RSLS vs. BIAF, ABT, ISRG, BSX, SYK, MDT, BDX, IDXX, EW, and RMD
Should you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include bioAffinity Technologies (BIAF), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), and ResMed (RMD). These companies are all part of the "medical" sector.
ReShape Lifesciences vs. Its Competitors
bioAffinity Technologies (NASDAQ:BIAF) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.
1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are held by institutional investors. 16.9% of bioAffinity Technologies shares are held by company insiders. Comparatively, 0.0% of ReShape Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, bioAffinity Technologies had 4 more articles in the media than ReShape Lifesciences. MarketBeat recorded 4 mentions for bioAffinity Technologies and 0 mentions for ReShape Lifesciences. bioAffinity Technologies' average media sentiment score of 0.47 beat ReShape Lifesciences' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.
ReShape Lifesciences has lower revenue, but higher earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks.
bioAffinity Technologies has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.
ReShape Lifesciences has a net margin of -69.71% compared to bioAffinity Technologies' net margin of -152.16%. ReShape Lifesciences' return on equity of -547.65% beat bioAffinity Technologies' return on equity.
Summary
bioAffinity Technologies and ReShape Lifesciences tied by winning 7 of the 14 factors compared between the two stocks.
Get ReShape Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ReShape Lifesciences Competitors List
Related Companies and Tools
This page (NASDAQ:RSLS) was last updated on 9/12/2025 by MarketBeat.com Staff
Free RSLS Stock Alerts